Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

After primary vaccination: Very common (> 10%): local reactions such as pain, redness and swelling at the injection site. Reduced appetite, fever, drowsiness, more easily irritated. Common (1-10%): abnormal crying, restlessness, viral infection, infection of the upper respiratory tract, bronchitis, conjunctivitis, coughing, vomiting, rhinitis. Uncommon (0.1-1%): Fatigue, abdominal pain, diarrhoea, obstipation, enteritis or gastroenteritis, sleepiness, infection, middle ear inflammation, eczema, dermatitis. Very rare (< 0.01%): convulsions, allergic reactions. After revaccination: fever (> 38%). Common (1-10%): diarrhoea, enteritis or gastroenteritis, candidiasis, middle ear inflammation, pharyngitis, dermatitis, rash. Uncommon (0.1-1%): sleeplessness, bronchial spasms, laryngitis, stridor. During the post-marketing phase, fainting or shock-like symptoms and anaphylactic reactions have been reported in other vaccines containing DTaP.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Consider the administration of vaccines containing whooping cough carefully if any of the following symptoms have occurred when previously given: high fever (> 40°C) within 48 hours of vaccination that is not attributable to any other cause; collapse or a shock-like condition within 48 hours of vaccination; continuous (≥ 3 hours) and inconsolable crying within 48 hours of vaccination; convulsions with or without fever within three days of vaccination. Be cautious if there is a history of progressive neurological conditions. Do not administer intravascularly under any circumstances. The immunogenicity of the vaccine can be reduced by immunosuppressive treatment or immunodeficiency. Triaxis Polio must not be given to people with incomplete or missing prior history of primary vaccination against diphtheria, tetanus or polio because it will be insufficiently effective.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

• ANTIINFECTIVES FOR SYSTEMIC USE
• VACCINES

BACTERIAL AND VIRAL VACCINES, COMBINED

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

References

1. GlaxoSmithKline BV, SPC Infanrix IPV RVG 34568, www.cbg-meb.nl, http://db.cbg-meb.nl/IB-teksten/h34568.pdf, (geraadpleegd 29 okt 2009)
2. RIVM, Rijksvaccinatieprogramma: Vaccinatieschema, 3 december 2019
3. GlaxoSmithKline BV, SmPC Boostrix Polio (RVG 35123 en 35124) 14-12-2018, www.geneesmiddeleninformatiebank.nl
4. Sanofi Pasteur Europe , SmPC Triaxis Polio (RVG 27569) 23-06-2020, www.geneesmiddeleninformatiebank.nl

Changes

Therapeutic Drug Monitoring

Overdose